Sakopoulos Sofia, Todman McWelling
Department of Psychology, The New School for Social Research, New York, NY 10011, USA.
Int J Mol Sci. 2025 Jul 11;26(14):6673. doi: 10.3390/ijms26146673.
Ketamine infusion therapy has gained recognition as an innovative treatment for treatment-resistant depression (TRD), demonstrating rapid and robust antidepressant effects. Its therapeutic promise is increasingly understood to involve molecular and neurobiological processes that promote neural plasticity and cognitive flexibility. These changes may create a unique window for psychotherapeutic interventions to take deeper effect. This retrospective chart review examined the clinical outcomes of individuals with TRD who received either single or repeated ketamine infusion(s), with or without weekly psychotherapy. Depression severity, measured by Beck Depression Inventory scores, was assessed pre-treatment and 30 days post-infusion(s). The results showed significant symptom reduction across all groups, with the most pronounced effects observed in those who received concurrent psychotherapy. While infusion number did not significantly alter outcomes, the integration of ketamine with psychotherapy appeared to enhance treatment response.
氯胺酮输注疗法已被公认为是一种针对难治性抑郁症(TRD)的创新治疗方法,显示出快速且显著的抗抑郁效果。人们越来越认识到其治疗前景涉及促进神经可塑性和认知灵活性的分子和神经生物学过程。这些变化可能为心理治疗干预产生更深入的效果创造一个独特的窗口。这项回顾性病历审查研究了接受单次或重复氯胺酮输注、有或没有每周心理治疗的TRD患者的临床结果。通过贝克抑郁量表评分衡量的抑郁严重程度在治疗前和输注后30天进行评估。结果显示所有组的症状均有显著减轻,在接受同步心理治疗的患者中观察到的效果最为明显。虽然输注次数并未显著改变结果,但氯胺酮与心理治疗的结合似乎增强了治疗反应。